Octave Bioscience secured $35.6 million in Series C funding alongside a $15.5 million non-dilutive term loan from Silicon Valley Bank to advance its proteomic diagnostic tests. The company’s MSDA test, launched in 2022, measures 18 blood proteins to assess multiple sclerosis disease activity. Octave plans to commercialize this test further and develop a Parkinson’s disease diagnostic. Investors including Merck Global Health Innovation Fund and Novartis participated, underscoring confidence in Octave’s precision neurology platform for neurodegenerative diseases.